Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

Inclusion Criteria: * Acute lymphocytic leukemia (ALL) in morphologic first complete remission (CR1) with high risk features defined as, but not limited to: evidence of adverse cytogenetics such as t(9;22), t(1;19), t(4;11), or mixed-lineage leukemia (MLL) rearrangements; presence of minimal residual disease; progenitor B-cell immunophenotype; high white blood cells (WBC) at diagnosis (\> 30,000/ul in B-ALL; \> 100,000/ul in T-ALL); or delayed attainment of CR (\> 4 weeks) after induction therapy; additional clinical characteristics deemed to confer a high relapse risk may be discussed with and approved by the Principal Investigator (PI) * Acute myeloid leukemia (AML) in CR1 EXCEPT patients with low-risk features defined as: * Inv 16 or t(8;21) in the absence of c-kit mutations * Normal karyotype who are FLT3-ITD-negative and NPM1-positive in the absence of c-kit mutations * Patients with respective "low-risk" features are eligible, however, if (i) more than 1 cycle of induction therapy was required to achieve CR1 (ii) the patient had a preceding myelodysplastic syndrome (MDS) other than myelofibrosis, or (iii) secondary AML * Acute leukemia in 2nd or greater CR (CR \>= 2) * Refractory or relapsed AML with =\< 10% bone marrow blasts and no circulating blasts or proven extramedullary disease * AML transformed from myelodysplastic syndrome (MDS) with \< 10% bone marrow blasts * MDS with following high risk features: * High risk cytogenetics (including, but not limite…